Resale S-1 Registration Statement Becomes Effective Permitting Certain Optionholders to Resell Shares Underlying Their Options

Saturday, July 3, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

LEWISBERRY, Pa., July 2 Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS) wishes to advise that its Form S-1 Resale Registration Statement has now been declared effective by the United States Securities and Exchange Commission ("SEC"). As previously advised, the Registration Statement simply removes restrictions which apply under US federal securities laws to the sale of shares underlying certain options previously issued by the Company.

The Registration Statement, while effective, allows the optionholders to freely trade the shares issued or issuable upon exercise of their options (other than affiliates of Unilife to whom certain re-sale restrictions will still apply). The Company is not issuing any new share capital and will not receive any proceeds from the issue of the shares (other than the exercise price payable by optionholders on exercise of their options).

The options to which this Registration Statement applies are the replacement Unilife Corporation options which were issued to optionholders upon the redomiciliation undertaken by the Unilife Group in January 2010.

A copy of the Form S-1 Resale Registration Statement can be viewed at the address below:

This press release shall not constitute an offer to issue or sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor Contacts (US): Todd Fromer / Garth Russell KCSA Strategic Communications Phone + 1 212-682-6300 Stuart Fine Carpe DM Inc Phone + 1 908 469 1788 Investor Contacts(Australia): Jeff Carter Unilife Corporation Phone + 61 2 8346 6500

SOURCE Unilife Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store